Precision Medicine Got Kidney Disease Wrong—Until Now

from Power to the Patients · host Brandon Li

Explore how variant functionalization is driving the future of mechanism-driven medicines as host Brandon interviews Jason Coloma, CEO of Maze Therapeutics, on Power to the Patients. Jason explains why most gene-disease associations fail to become therapies, how APOL1-mediated kidney disease reveals the power of precision nephrology, and what it actually takes to build an integrated genetics-to-drug-discovery platform.

Episode metadata supplied by the publisher feed · Published Apr 1, 2026

Embed this episode

Attribution link and audio player

Ready to play

Precision Medicine Got Kidney Disease Wrong—Until Now

0:00 42:13

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Power to the Patients?

This episode is 42 minutes long.

When was this Power to the Patients episode published?

This episode was published on April 1, 2026.

Can I download this Power to the Patients episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!